Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-(L)1”

80 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 80 results

Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Post-approval studies (Phase 4)Not Yet RecruitingNCT07004335
What this trial is testing

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Who this might be right for
PD-(L)1CTLA-4Advanced Melanoma+3 more
Hebei Medical University Fourth Hospital 40
Early research (Phase 1)Looking for participantsNCT04977167
What this trial is testing

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Who this might be right for
Solid TumorLymphoma
HitGen Inc. 96
Large-scale testing (Phase 3)Looking for participantsNCT06738251
What this trial is testing

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Who this might be right for
Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd. 402
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06118645
What this trial is testing

Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Who this might be right for
Gastric Adenocarcinoma
China Medical University, China 40
Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Not applicableUnknownNCT06194695
What this trial is testing

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma Non-resectable
Ze-yang Ding, MD 100
Early research (Phase 1)Study completedNCT05225584
What this trial is testing

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Who this might be right for
Non Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)+3 more
Kymera Therapeutics, Inc. 56
Early research (Phase 1)UnknownNCT00343954
What this trial is testing

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

Who this might be right for
Sickle Cell Disease
Angiogenix 12
Large-scale testing (Phase 3)Active Not RecruitingNCT05382299
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerPD-L1 Negative
Gilead Sciences 623
Testing effectiveness (Phase 2)Looking for participantsNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 345
Large-scale testing (Phase 3)Looking for participantsNCT06524544
What this trial is testing

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI) 320
Testing effectiveness (Phase 2)Study completedNCT04819373
What this trial is testing

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Who this might be right for
Tumor, Solid
Eikon Therapeutics 1
Testing effectiveness (Phase 2)Looking for participantsNCT06642792
What this trial is testing

AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin Lymphoma
Akeso 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07288034
What this trial is testing

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Who this might be right for
Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
City of Hope Medical Center 535
Testing effectiveness (Phase 2)Active Not RecruitingNCT05882734
What this trial is testing

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Who this might be right for
Non-Small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 61
Testing effectiveness (Phase 2)Ended earlyNCT03952325
What this trial is testing

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 294
Testing effectiveness (Phase 2)Study completedNCT04993677
What this trial is testing

SEA-CD40 Given With Other Drugs in Cancers

Who this might be right for
MelanomaCarcinoma, Non-Small- Cell Lung
Seagen Inc. 77
Testing effectiveness (Phase 2)Study completedNCT04144517
What this trial is testing

ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Mural Oncology, Inc 14
Not applicableNot Yet RecruitingNCT07186868
What this trial is testing

QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

Who this might be right for
Recurrent Cervical CancerMetastatic Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 25
Load More Results